Stoke Therapeutics is a biotechnology company developing RNA-based medicines for rare genetic diseases. Its TANGO platform uses antisense oligonucleotides to increase gene expression, aiming to help patients produce more protein from their own genes in conditions where one working copy of a gene is insufficient. The company’s lead program, STK‑001, is in development for Dravet syndrome, a genetic epilepsy associated with SCN1A haploinsufficiency. Other programs focus on genetic neurology and rare disease indications.
Lead global clinical trials at Stoke Therapeutics, which develops RNA medicines. The role oversees CROs, vendors, study delivery, risks, budgets, and compliance.